Zydus Lifesciences gets USFDA final nod for Bortezomib for Injection; Stock sheds 1.5%

4 May 2022 , 09:59 AM

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) has received final approval from the United States Food and Drug Administration (USFDA) to market Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial (USRLD: Velcade).

As per the filing, Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma. The medication works by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus Hospira. Velcade has a market size of USD 1,172mn (as per IQVIA MAT Mar’22).

The group now has 331 approvals and has so far filed over 400 ANDAs since the commencement of filing process in FY 2003-04, said pharma company.

At around 10:01 AM, Zydus Lifesciences was trading at Rs344.80 apiece down by Rs5.7 or 1.63% from its previous closing of Rs350.50 apiece on the BSE.